Amphastar Pharmaceuticals (AMPH) Lifted to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a sell rating to a hold rating in a research note issued to investors on Wednesday morning.

According to Zacks, “Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. “

Several other research analysts have also commented on AMPH. BidaskClub lowered shares of Amphastar Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Monday, February 25th. Needham & Company LLC set a $25.00 price target on shares of Amphastar Pharmaceuticals and gave the stock a buy rating in a research note on Friday, November 9th. TheStreet upgraded shares of Amphastar Pharmaceuticals from a c+ rating to a b- rating in a research note on Friday, January 11th. Jefferies Financial Group restated a buy rating and set a $26.00 price target on shares of Amphastar Pharmaceuticals in a research note on Wednesday, November 14th. Finally, Wells Fargo & Co restated a buy rating on shares of Amphastar Pharmaceuticals in a research note on Friday, November 9th. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Amphastar Pharmaceuticals has a consensus rating of Buy and an average target price of $23.33.

AMPH stock opened at $25.28 on Wednesday. Amphastar Pharmaceuticals has a 12-month low of $14.40 and a 12-month high of $25.34. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.02 and a quick ratio of 1.34. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of 66.53, a P/E/G ratio of 1.37 and a beta of 1.39.

In other news, insider Jason B. Shandell sold 16,630 shares of the stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $22.44, for a total transaction of $373,177.20. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO William J. Peters sold 10,000 shares of the stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $22.40, for a total transaction of $224,000.00. Following the transaction, the chief financial officer now owns 133,381 shares in the company, valued at approximately $2,987,734.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 400,774 shares of company stock worth $8,740,419. 31.50% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of AMPH. BlackRock Inc. grew its stake in Amphastar Pharmaceuticals by 4.7% in the 3rd quarter. BlackRock Inc. now owns 5,987,805 shares of the company’s stock valued at $115,205,000 after buying an additional 267,622 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Amphastar Pharmaceuticals by 7.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,909,883 shares of the company’s stock worth $36,746,000 after purchasing an additional 140,350 shares during the last quarter. Martingale Asset Management L P acquired a new stake in Amphastar Pharmaceuticals in the 3rd quarter worth $2,033,000. Renaissance Technologies LLC grew its position in Amphastar Pharmaceuticals by 104.3% in the 3rd quarter. Renaissance Technologies LLC now owns 186,100 shares of the company’s stock worth $3,581,000 after purchasing an additional 95,000 shares during the last quarter. Finally, Assenagon Asset Management S.A. acquired a new stake in Amphastar Pharmaceuticals in the 4th quarter worth $1,312,000. Institutional investors and hedge funds own 45.62% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Read More: Gross Domestic Product (GDP)

Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.